HRYZ (Shanghai) Biotech

Shanghai Haoyuan Chemexpress is a prominent China-based company providing high-end pharmaceutical research and development services and products. Founded in 2006 and headquartered in Shanghai, the company operates as a specialized CRO and CDMO, focusing on the discovery, development, and manufacturing of small molecule drug intermediates and active pharmaceutical ingredients (APIs). Haoyuan Chemexpress is particularly distinguished for its advanced technology platforms in Antibody-Drug Conjugates (ADC) and Proteolysis Targeting Chimeras (PROTAC), offering an extensive library of molecular blocks, linkers, and ligands. The company supports a global client base, ranging from virtual biotech startups to large multinational pharmaceutical corporations, across various therapeutic areas including oncology and metabolic diseases. Listed on the Shanghai Stock Exchange's STAR Market, Haoyuan Chemexpress continues to expand its manufacturing capabilities and integrated service offerings to accelerate drug innovation.